Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India.

Cetuximab is the first biosimilar developed for Eli Lilly and Company’s Cetuximab, a monoclonal antibody medication used in the treatment of various types of cancer, including head and neck cancer and metastatic colorectal cancer.

This collaboration between Lupin and Enzene Biosciences signifies a significant milestone in expanding therapeutic options and fostering innovation in the critical field of head and neck cancer treatment. Cetuximab has received approval from the Drug Controller General of India (DCGI) for its effectiveness in addressing head and neck cancer, particularly Squamous Cell Carcinoma of the Head and Neck (SCCHN). This makes it a crucial solution for patients with recurrent locoregional or metastatic conditions. Cetuximab is available as a 100mg vial.

Head and neck cancer presents a formidable public health challenge in India, with an annual incidence of over 100,000 new cases. This malignancy affects vital regions of the head and neck, including the oral cavity, pharynx, larynx, and sinuses.

The diagnosis of head and neck cancer often occurs at advanced stages, making effective treatment increasingly challenging. Consequently, the disease carries a substantial burden, resulting in significant difficulties in providing effective treatment and contributing to high mortality rates.

Through this partnership, Lupin and Enzene Biosciences aim to address the pressing healthcare concerns associated with head and neck cancer by introducing the first biosimilar Cetuximab. The collaboration leverages their combined expertise to provide patients with a more accessible and cost-effective treatment option.

The approval from the DCGI validates the efficacy of Cetuximab in combating head and neck cancer, offering hope for patients in need of effective treatments.

Rajeev Sibal — Lupin President of India Region Formulations said: “The launch of first biosimilar Cetuximab reflects our steadfast dedication to improving access to solutions and enhancing patient outcomes. Through this collaboration, we empower healthcare professionals with a transformative and affordable solution that holds the potential to make a significant impact on the lives of those facing this challenging disease.”

The introduction of the biosimilar Cetuximab holds great promise in revolutionizing the treatment landscape for head and neck cancer in India. Through joint efforts and resources, Lupin and Enzene Biosciences aspire to make a meaningful impact on patient care and address the unmet medical needs associated with this devastating condition.

  Alkem Laboratories, Cancer treatment, Cetuximab, Colorectal cancer, DCGI, Drug Controller General of India, Eli Lilly and Company, Enzene Biosciences, Head and neck cancer, India, Lupin, Metastatic colorectal cancer, Rajeev Sibal